To compare the slope of cycle threshold(Ct) values of nasopharyngeal swabs in people receiving Triazavirin versus placebo;To assess the proportion of patients who progress to severe COVID-19 and the proportion who need ICU or die.;To determine the proportion of patients who stop taking either placebo/Triazavirin;To determine the proportion of patients who develop grade 3 or grade 4 adverse events on treatment

To compare the slope of cycle threshold(Ct) values of nasopharyngeal swabs in people receiving Triazavirin versus placebo;To assess the proportion of patients who progress to severe COVID-19 and the proportion who need ICU or die.;To determine the proportion of patients who stop taking either placebo/Triazavirin;To determine the proportion of patients who develop grade 3 or grade 4 adverse events on treatment